Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 6/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL538809 | 0.90 | PDK2 (0.41) | PDK2 | |
| SCHEMBL539158 | 0.83 | PDK2 (0.39) | PDK2 | |
| SCHEMBL539157 | 0.79 | PDK2 (0.50) | PDK2 | |
| SCHEMBL538549 | 0.78 | MAPT (0.38) | PDK2 | |
| SCHEMBL15470841 | 0.78 | PDK2 (0.48) | PDK2 | |
| SCHEMBL538516 | 0.77 | PDK2 (0.56) | PDK2 | |
| SCHEMBL538808 | 0.72 | PDK2 (0.44) | PDK2 | |
| SCHEMBL538748 | 0.72 | PDK2 (0.49) | PDK2 | |
| SCHEMBL10249558 | 0.68 | MDM2 (0.36) | PDK2 | |
| SCHEMBL538807 | 0.68 | PDK2 (0.56) | PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12351601-B2 | Method for producing peptide continuously | AJINOMOTO CO., INC. (JP) | 2025-07-08 | — | — | US | claimed |
| US-20220041648-A1 | METHOD FOR PRODUCING PEPTIDE CONTINUOUSLY | AJINOMOTO CO., INC. (JP) | 2022-02-10 | — | — | US | claimed |
| US-9029504-B2 | Fluorene compound | AJINOMOTO CO., INC. (JP) | 2015-05-12 | — | — | US | claimed |
| US-20140046022-A1 | FLUORENE COMPOUND | AJINOMOTO CO., INC. (JP) | 2014-02-13 | — | — | US | claimed |
| EP-2415744-A1 | FLUORENE COMPOUND | Ajinomoto Co., Inc. (JP) | 2012-02-08 | — | — | EP | claimed |
| US-20100240867-A1 | FLUORENE COMPOUND | AJINOMOTO CO. INC. (JP) | 2010-09-23 | — | — | US | claimed |
| US-12351601-B2 | Method for producing peptide continuously | AJINOMOTO CO., INC. (JP) | 2025-07-08 | — | — | US | disclosed |
| US-20220041648-A1 | METHOD FOR PRODUCING PEPTIDE CONTINUOUSLY | AJINOMOTO CO., INC. (JP) | 2022-02-10 | — | — | US | disclosed |
| US-9334302-B2 | Method for removing FMOC group | AJINOMOTO CO., INC. (JP) | 2016-05-10 | — | — | US | disclosed |
| US-9029504-B2 | Fluorene compound | AJINOMOTO CO., INC. (JP) | 2015-05-12 | — | — | US | disclosed |
| US-20140296483-A1 | METHOD FOR REMOVING FMOC GROUP | AJINOMOTO CO., INC. (JP) | 2014-10-02 | — | — | US | disclosed |
| US-20140046022-A1 | FLUORENE COMPOUND | AJINOMOTO CO., INC. (JP) | 2014-02-13 | — | — | US | disclosed |
| US-8569453-B2 | Fluorene compound | AJINOMOTO CO., INC. (JP) | 2013-10-29 | — | — | US | disclosed |
| EP-2415744-A1 | FLUORENE COMPOUND | Ajinomoto Co., Inc. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20100240867-A1 | FLUORENE COMPOUND | AJINOMOTO CO. INC. (JP) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220041648-A1 | METHOD FOR PRODUCING PEPTIDE CONTINUOUSLY | VIP, NPPA, NGLY1 | PDK2 4375/4885 |
| US-20140046022-A1 | FLUORENE COMPOUND | NPPA, FURIN, SFPQ | PDK2 3174/4885 |
| US-20140296483-A1 | METHOD FOR REMOVING FMOC GROUP | ESD, HM13, FURIN | PDK2 4173/4885 |
| US-20100240867-A1 | FLUORENE COMPOUND | NPPA, FURIN, SFPQ | PDK2 3174/4885 |
| US-12351601-B2 | Method for producing peptide continuously | VIP, NPPA, NGLY1 | PDK2 4375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.